Trump administration pushes U.S. at-home kidney care, transplant availability

NEW YORK/WASHINGTON (Reuters) – The Trump administration on Wednesday set goals to move more kidney disease treatment into patients’ homes and increase transplants while reducing the U.S. reliance on more costly dialysis clinics.

President Donald Trump signed an executive order underscoring these goals, and the U.S. health agency said it would test new payment structures, including one that rewards end-stage renal disease facilities and doctors who meet targets in these areas.

The U.S. government spends $114 billion each year to treat chronic kidney disease and end-stage renal disease.

Nearly 15% of the U.S. adult population was suffering from chronic kidney disease in 2018, fueled by growing rates of diabetes and hypertension, according to the government’s U.S. Renal Data System.

Trump, speaking to patients, advocacy groups and health officials at a Washington D.C. event at the Ronald Reagan Building and International Trade Center, said the government effort would increase the number of available organs for transplant.

“Many, many people are dying while they wait,” he said.

Trump’s wife, Melania, was hospitalized for several days in May of 2018 after an embolization procedure to treat a benign kidney condition.

U.S. Department of Health and Human Services (HHS) Secretary Alex Azar said the government aims to reduce the number of Americans developing end-stage renal disease by 25% by 2030, to have 80% of new patients either receive dialysis at home or undergo kidney transplants by 2025, and to double the number of kidneys available for transplant by 2030.

The government wants healthcare providers to focus on prevention and earlier treatment.

“The way the system is set up, it’s kind of pushing people towards dialysis,” Seema Verma, head of the Centers for Medicare and Medicaid Services, said in a phone interview.

NEW PAYMENT METHODS

Health officials said about 12% of Americans receive dialysis at home, in part because of a payment structure that pays doctors more when they use pricier dialysis centers. Reuters has previously reported on the government’s intention to change its payment methods.

U.S. health officials declined to provide details on anticipated cost savings from the new treatment goals.

The government proposed testing several new payment methods, including one that will apply to about half of Medicare patients with end-stage renal disease across the country.

In that scheme, some facilities and clinicians chosen at random would receive higher or lower payments based on the rate at which they increase the use of home dialysis and transplants.

If finalized, that program would go into effect Jan. 1, 2020, and run through June 20, 2026. Other voluntary payment trials would add financial incentives for health care providers managing patients with late-stage chronic kidney disease.

The U.S. kidney care market is dominated by two players: DaVita Inc and Fresenius Medical Care AG, which operate more than 5,000 U.S. dialysis clinics and control around 70% of the market.

DaVita shares rose 4.2% to $54.80, but were still trading 5% lower than before news of the pending kidney care announcement broke on Monday. Fresenius Medical closed up 1.65% at 67.74 euros in Frankfurt trading.

Leerink analyst Ana Gupte said the sell-off had likely been overdone and that some details of the new rule were still to come. “It is unclear at this point what the incentives are for a shift to home dialysis,” Gupte said by email.

Healthcare has been a key issue for Trump, who tried and failed to replace the Affordable Care Act, also known as Obamacare, but has rolled back key provisions, such as the penalty for not having health insurance. The ACA is being challenged in court.

The Republican president has also pushed drug companies to lower their prices. On Monday, a federal court struck down a new rule that would have forced pharmaceutical companies to include the list prices of their drugs in television advertising.

Reporting by Caroline Humer in New York and Roberta Rampton in Washington D.C.; Editing by Susan Thomas and Bill Berkrot

Source

more recommended stories

  • Oklahoma seeks to hold J&J responsible for opioid crisis as trial ends

    NORMAN, Okla. (Reuters) – Lawyers for.

  • Healthy living may help offset genetic risk of dementia: study

    LONDON (Reuters) – Living healthily with.

  • Democrats take aim as Trump abandons drug pricing plan

    WASHINGTON (Reuters) – Democrats see U.S..

  • U.S. appeals court blocks Trump administration birth control exemptions

    (Reuters) – A federal appeals court.

  • China vows to tackle dead pig scam amid swine fever epidemic

    FILE PHOTO: Piglets are seen by.

  • Alberta joins Ontario in pulling some CannTrust weed products

    TORONTO (Reuters) – Alberta is placing.

  • U.S. appeals court signals sympathy to bid to strike down Obamacare

    NEW ORLEANS (Reuters) – A federal.

  • U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

    (Reuters) – A federal judge on.

  • Intra-Cellular drug fails one of two bipolar depression studies; shares fall

    (Reuters) – Intra-Cellular Therapies Inc said.

  • China reports new African swine fever outbreak in Guangxi region

    BEIJING (Reuters) – China’s southwestern region.

  • Weed ban means no Rocky Mountain high for Canada’s Calgary Stampede

    CALGARY, Alberta (Reuters) – Canada’s Calgary.

  • Weightlifting better at reducing heart fat than aerobic exercise

    Obese people who engaged in resistance.

  • Sydney’s city council reviews use of Bayer’s Roundup weed killer amid cancer fears

    SYDNEY (Reuters) – Sydney’s city council.

  • Bulgaria confirms two cases of African swine fever

    SOFIA (Reuters) – Bulgaria has confirmed.

  • FDA approves Karyopharm Therapeutics’ blood cancer drug

    (Reuters) – The U.S. Food and.

  • Facebook to tackle content with misleading health claims

    FILE PHOTO: The Facebook logo is.

  • FDA ties three deaths to Edwards Lifesciences’ recalled heart devices

    (Reuters) – The U.S. Food and.

  • India asks its states not to partner with Philip Morris-funded foundation

    NEW DELHI (Reuters) – India’s health.

  • U.S. federal court delays adoption of healthcare rule on abortion

    FILE PHOTO – A imaging table.

  • China tightens vaccine management after scandals

    FILE PHOTO – A nurse prepares.

  • U.S wages lost to unpaid family care to hit $147 billion by 2050

    As the U.S. population ages, the.

  • U.S. ‘gag rule’ linked to 40% jump in abortions in parts of Africa

    LONDON (Reuters) – A decades-old U.S..

  • Study shows major real-world impact of cervical cancer vaccines

    LONDON, June 26 (Reuters) – Vaccination.

  • Glyphosate use will eventually end, Merkel says

    German Chancellor Angela Merkel attends a.

  • Unproven stem cell therapies often peddled by doctors without training

    At U.S. clinics advertising unproven stem.

  • Teleflex recalls breathing tubes worldwide after reports of 4 deaths

    (Reuters) – Teleflex Inc said on.

  • In border camps, Syrians rely on doctors in trucks and tents

    AZAZ, Syria (Reuters) – The Syrian.

  • Thailand bans pig imports from Laos after African swine fever outbreak

    BANGKOK (Reuters) – Thailand will ban.

  • FDA approves drug for loss of sexual desire in women

    (Reuters) – The U.S. drug regulator.

  • Missouri orders lone abortion clinic to close; judge keeps it open for now

    ST. LOUIS (Reuters) – Missouri health.

  • Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

    NEW YORK (Reuters) – Merck &.

  • Strobing stage lights could up risk of epileptic seizures

    (Reuters Health) – Flashing light effects.